On August 12, Kang Fang Biotech announced that the company's application for the marketing of a new drug for first-line treatment of advanced squamous non-small cell lung cancer with the world's first line chemotherapy, the cornerstone of tumor immunity 2.0, has been approved for marketing by the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.